Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2009-10-14 07:45 |
Pharming confirms successful closing of offer on convertible bonds
|
English | 68.9 KB | ||
| 2009-10-08 17:57 |
Pharming finalizes conversion of 70% of outstanding bonds
|
English | 174.6 KB | ||
| 2009-10-05 08:07 |
Pharming secures additional € 10 million financing from Yorkville Advisors
|
English | 71.6 KB | ||
| 2009-10-01 08:57 |
PHARMING PROVIDES UPDATE ON OUTSTANDING SHARES
|
English | 68.1 KB | ||
| 2009-09-30 09:07 |
Pharming receives commitment for conversion of 70% of outstanding bonds
|
English | 75.1 KB | ||
| 2009-09-30 08:31 |
PHARMING RECEIVES COMMITMENT FOR CONVERSION OF 70% OF OUTSTANDING BONDS
|
English | 111.4 KB | ||
| 2009-09-30 08:31 |
PHARMING RECEIVES COMMITMENT FOR CONVERSION OF 70% OF OUTSTANDING BONDS
|
English | 75.1 KB | ||
| 2009-09-24 08:04 |
PHARMING’S MARKETING AUTHORISATION APPLICATION FOR RHUCIN VALIDATED BY THE EURO…
|
English | 82.2 KB | ||
| 2009-09-22 09:29 |
DNAGE initiates observational study in children suffering from cockayne syndrome
|
English | 75.1 KB | ||
| 2009-09-21 07:38 |
Pharming announces offer to holders of convertible bonds with financial support…
|
English | 122.0 KB | ||
| 2009-09-18 08:38 |
Pharming to present at UBS Global Life Sciences Conference
|
English | 68.2 KB | ||
| 2009-09-11 08:38 |
PHARMING PROVIDES UPDATE ON OUTSTANDING NUMBER OF SHARES
|
English | 68.2 KB | ||
| 2009-09-03 08:50 |
PHARMING SUBMITS MARKETING AUTHORISATION APPLICATION FOR RHUCIN® TO THE EMEA
|
English | 155.6 KB | ||
| 2009-08-28 09:11 |
Pharming gives update on outstanding number of shares
|
English | 146.2 KB | ||
| 2009-08-14 10:48 |
FDA approves Investigational New Drug application for Prodarsan® in Cockayne Sy…
|
English | 160.0 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
